September 20, 2016
BioCentury
reports that Australia's Therapeutic Goods Administration (TGA) is planning to implement new approval pathways in an effort to improve and speed access to therapeutics. Among the new pathways reported is an expedited approval pathway that allows for accelerated assessment of new medicines - potentially allowing them to come to market three months sooner than the current framework -and a provisional approval pathway, which could speed up approval by as much as two years. For more on this story,
click here
.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.